Truist analyst Srikripa Devarakonda lowered the firm’s price target on Biogen (BIIB) to $220 from $302 and keeps a Buy rating on the shares as ...

Analysis of Biogen's stock performance in 2024, focusing on sales struggles, financial health, and valuation. Read more here.

The stock's fall snapped a two-day winning streak.

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Biogen (BIIB – Research Report) yesterday and set a price target of ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...

The stock’s performance has been below most large drugmakers’ performance. Biogen's revenues declined 3% in the first nine months of 2024. Sales of Biogen’s key multiple sclerosis (“MS ...

Private Medicare plans must cover Biogen's ALS drug, US agency says Healthcare & Pharmaceuticalscategory· December 13, 2024 Corcept Therapeutics said on Wednesday its experimental drug failed to ...

Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains sluggish, falling below consensus projections through 2030. Challenges ...

Biogen Inc. closed $118.40 short of its 52-week high ($268.30), which the company achieved on January 3rd.